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Abstract  Age  related  macular  degeneration  (AMD)  is  the  leading  cause  of  blindness  in  individ-
uals older  than  65  years  of  age.  It  is  a  multifactorial  disorder  and  identiﬁcation  of  risk  factors
enables individuals  to  make  lifestyle  choices  that  may  reduce  the  risk  of  disease.  Collabora-
tion between  geneticists,  ophthalmologists,  and  optometrists  suggests  that  genetic  risk  factors
play a  more  signiﬁcant  role  in  AMD  than  previously  thought.  The  most  important  genes  are
associated  with  immune  system  modulation  and  the  complement  system,  e.g.,  complement
factor H  (CFH),  factor  B  (CFB),  factor  C3,  and  serpin  peptidase  inhibitor  (SERPING1).  Genes
associated  with  membrane  transport,  e.g.,  ATP-binding  cassette  protein  (ABCR)  and  voltage-
dependent  calcium  channel  gamma  3  (CACNG3),  the  vascular  system,  e.g.,  ﬁbroblast  growth
factor 2  (FGF2),  ﬁbulin-5,  lysyl  oxidase-like  gene  (LOXL1)  and  selectin-P  (SELP),  and  with  lipid
metabolism,  e.g.,  apolipoprotein  E  (APOE)  and  hepatic  lipase  (LIPC)  have  also  been  implicated.
In addition,  several  other  genes  exhibit  some  statistical  association  with  AMD,  e.g.,  age-related
maculopathy  susceptibility  protein  2  (ARMS2)  and  DNA  excision  repair  protein  gene  (ERCC6)  but
more research  is  needed  to  establish  their  signiﬁcance.  Modiﬁable  risk  factors  for  AMD  should
be discussed  with  patients  whose  lifestyle  and/or  family  history  place  them  in  an  increased  risk
category. Furthermore,  calculation  of  AMD  risk  using  current  models  should  be  recommended
as a  tool  for  patient  education.  It  is  likely  that  AMD  management  in  future  will  be  increas-
ingly inﬂuenced  by  assessment  of  genetic  risk  as  such  screening  methods  become  more  widely
available.
© 2013  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
PALABRAS  CLAVE Factores  genéticos  de  riesgo  y  degeneración  macular  asociada  a  la  edad  (DMAE)
Degeneración
macular  asociada  a  la Resumen  La  degeneración  macular  asociada  a  la  edad  (DMAE)  constituye  la  causa  principal
ayores  de  65  an˜os.  Se  trata  de  un  trastorno  multifactorial,  en  elde ceguera  en  personas  medad  (DMAE);
Genética; que la  identiﬁcación  de  los  factores  de  riesgo  permite  a  las  personas  la  elección  de  aquellos
estilos de  vida  que  pueden  reducir  el  riesgo  de  la  enfermedad.  La  colaboración  entre  genetistas,
oftalmólogos  y  optometristas  sugiere  que  los  factores  genéticos  de  riesgo  juegan  un  papel  más
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Factores  modiﬁcables
del  riesgo;
Factor  H  de
complemento  (CFH);
Puntuaciones  de
evaluación  del  factor
de  riesgo
signiﬁcativo  en  la  DMAE  que  lo  que  se  pensaba  hasta  ahora.  Los  genes  más  importantes  están
asociados  a  la  modulación  del  sistema  inmune  y  al  sistema  del  complemento,  como  el  factor
H (CFH),  el  factor  B  (CFB)  y  el  factor  C3  del  complemento,  y  el  inhibidor  de  la  peptidasa  tipo
serpina (SERPING1).  También  se  ha  implicado  a  los  genes  asociados  al  transporte  a  través  de
membranas,  como  las  proteínas  cassette  de  unión  a  ATP  (ABC)  y  la  subunidad  gamma  3  de  los
canales del  calcio  dependientes  de  voltaje  (CACNG3),  al  sistema  vascular,  como  el  factor  2
de crecimiento  de  ﬁbroblastos  (FGF2),  la  ﬁbulina  5,  los  genes  de  tipo  lisil  oxidasa  (LOXL1)  y
la selectina-P  (SELP),  y  al  metabolismo  lipídico,  como  la  apolipoproteína  E  (APOE)  y  la  lipasa
hepática  (LIPC).  Además,  diversos  otros  genes  muestran  también  cierta  asociación  estadística
con la  DMAE,  como  la  proteína  2  de  susceptibilidad  a  la  maculopatía  asociada  a  la  edad  (ARMS2)
y el  gen  de  la  proteína  de  reparación  de  la  escisión  de  ADN  (ERCC6),  aunque  se  precisa  seguir
investigando  para  establecer  su  signiﬁcación.  Los  factores  modiﬁcables  del  riesgo  de  DMAE
deberán ser  discutidos  con  los  pacientes  cuyo  estilo  de  vida  y/o  historia  familiar  les  sitúan  en
una categoría  de  riesgo  incrementado.  Además,  debería  recomendarse  el  cálculo  del  riesgo  de
DMAE utilizando  los  modelos  actuales,  como  herramienta  de  educación  al  paciente.  Es  previsible
que el  tratamiento  futuro  de  la  DMAE  se  vea  crecientemente  inﬂuenciado  por  la  evaluación  del
riesgo genético,  y  que  por  tanto  estos  métodos  sean  cada  vez  mas  ampliamento  aplicados.
© 2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
derechos reservados.
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Age-related  macular  degeneration  (AMD)  is  the  most  impor-
tant  cause  of  blindness  in  industrialized  countries  in
individuals  over  65  years  of  age.  In  the  United  Kingdom,  for
example,  overall  prevalence  of  late  AMD  is  2.4%  of  the  pop-
ulation  aged  50  years  or  more  (Table  1)  increasing  to  4.8%
in  those  65  years  of  age  or  more  and  12.2%  in  individuals
greater  than  80  years  of  age.1--4 As  a  consequence,  there
are  estimated  to  be  513,000  individuals  currently  in  the  UK
with  the  visual  impairment  characteristic  of  AMD  suitable
for  registration  as  seriously  visually  impaired,  the  number
of  female  cases  being  greater  than  males.  This  ﬁgure  is  pre-
dicted  to  rise  to  679,000  by  20204 as  the  proportion  of  more
elderly  individuals  in  the  population  continues  to  increase,
a  phenomenon  likely  to  be  repeated  in  many  countries.
There  are  two  forms  of  AMD,  viz.,  the  ‘atrophic’  or
‘dry’  form  and  the  ‘exudative’  or  ‘wet’  form.  The  dry
form  is  characterized  by  degeneration  of  the  macular  pig-
ment  epithelium,  choriocapillaris,  and  photoreceptor  cells.
Larger  areas  of  degeneration  result  from  the  merging  of
small  areas  of  atrophy  and  this  state  is  often  referred  to
Table  1  Estimated  prevalence  and  number  of  cases  of  late-
stage  age-related  macular  degeneration  (AMD)  in  the  UK,
CL =  95%  conﬁdence  interval.1--4
Overall  prevalence  2.4%  (CL:  1.7--3.3%)
Estimated  number  of  cases  513,000  (CL:
363,000--699,000)
Estimated  new  cases  per  year 71,244(CL:
41,100--120,900)
Projected  increase  by  2020  679,000
Late  AMD,  number  of  females  314,000
Late  AMD,  number  of  males  192,000
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Ss  ‘geographic  atrophy’.  By  contrast,  in  the  wet  form,  new
horoidal  vessels  are  formed  (‘neovascularisation’)  and  ulti-
ately,  retinal  detachment,  edema,  and  hemorrhage  may
ccur  resulting  in  degeneration  of  the  macula.
In  the  last  decade,  collaboration  between  geneticists,
phthalmologists,  and  optometrists  has  revealed  signiﬁ-
ant  evidence  that  genetic  factors  are  involved  in  AMD5--8
nd  play  a  signiﬁcant  role  in  the  disease  alongside  other
isk  factors  such  as  smoking,9--12 diet,13--18 and  exposure  to
unlight.19,20 Several  genes  have  now  been  implicated  as
ossible  risk  factors,21--26 the  strongest  case  being  made  for
enes  involved  in  immune  modulation  and  the  complement
ystem.  Hence,  genetic  predisposition  to  AMD  may  increase
usceptibility  to  other  risk  factors  such  as  smoking,  diet,
nd  exposure  to  sunlight.  The  objectives  of  this  review
re  to  discuss  the  results  of  these  interdisciplinary  stud-
es  and  most  speciﬁcally  to  identify  those  genes  that  have
een  associated  with  an  increased  risk  of  AMD.  These  genes
re  discussed  in  ﬁve  main  categories:  (1)  immune  modula-
ion  and  the  complement  system,  (2)  membrane  transport,
3)  blood  vessel  development  and  vascular  modulation,  (4)
ipid  metabolism,  and  (5)  miscellaneous  genes.  In  addition,
nsights  that  these  genes  provide  as  to  pathogenesis  of  AMD
ogether  with  protective  factors,  modiﬁable  risk  factors,
nd  risk  factor  assessment  scores  are  also  discussed.  A  list
f  abbreviation  and  acronyms  used  in  this  review  is  given  in
able  2.
enes implicated in AMD
any  of  the  genes  implicated  as  possible  risk  factors  for
MD  involve  single  nucleotide  polymorphisms  (SNP)  in
hich  one  amino  acid  within  the  protein  is  substituted  for
nother.  Many  substitutions  commonly  result  from  ‘missense
utations’,  i.e.,  the  alteration  of  one  base  within  a  codon.
NP  may  have  varying  consequences.  Those  mutations
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Table  2  List  of  abbreviations  used  in  the  text.
ABCR  Adenosine  triphosphate  (ATP)-binding
cassette  rim  protein
ADP Adenosine  diphosphate
ATP  Adenosine  triphosphate
AMD  Age-related  macular  degeneration
APOE  Apolipoprotein  E
AREDS  Age  Related  Eye  Disease  Study
ARMS2  Age-related  maculopathy  susceptibility
protein  2
C3 Complement  factor  3
CACNG3  Voltage-dependent  calcium  channel
gamma-3
CFB Complement  factor  B
CFH  Complement  factor  H
dGI  Dietary  glycemic  index
ERCC6  DNA  excision  repair  protein
FGF2  Fibroblast  growth  factor  2
HTRA1  Serum  peptidase  1
IDL Intermediate  density  lipoprotein
LDL  Low  density  lipoprotein
LIPC  Hepatic  lipase
LOXL1  Lysyl  oxidase-like  1
MtDNA  Mitochondrial  DNA
p,q  Short  and  long  arms  of  chromosome
ROS  Reactive  oxygen  species
SELP  Selectin-P
SNP  Single  nucleotide  polymorphism
Tr Transferrin
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allowing  the  gene  to  be  located  to  the  short  arm  of  chromo-
some  1  near  to  the  centromere  (1p21-p22.1).  A  large  number
of  mutations  of  the  ABCR  gene  have  now  been  identiﬁed  indi-hich  give  rise  to  the  substitution  of  a  similar  amino
cid  within  a  protein,  such  as  valine  for  alanine,  result  in
ittle  protein  modiﬁcation.  By  contrast,  other  substitutions
ay  be  of  greater  consequence,  resulting  in  modiﬁed
rotein  structure,  through  greater  numbers  of  disulphide
ridges,  modiﬁed  hydrophobicity  and  charge,  which  in
urn,  compromise  protein  function  and  interaction  with
ther  molecules.  A  further  two  types  of  substitution  are
ess  common  but  potentially  more  disruptive  than  missense
utations.  First,  a  codon  is  modiﬁed  by  base  substitution
rom  one  coding  for  an  amino  acid  such  as  glutamate,  to
 stop  or  termination  codon  (‘null  mutation’  or  ‘nonsense
utation’)  and  frequently  results  in  a truncated  protein
ith  little  natural  function.  Second,  ‘splice-site’  mutations,
.e.,  a  substitution  in  a  region  separating  an  exon  from  an
ntron  can  result  in  the  incorporation  of  intron  DNA  into  pro-
ein  synthesis,  resulting  in  proteins  markedly  different  from
heir  natural  counterparts.  These  genetic  changes  often
ccur  as  natural  allelic  variations  within  the  population  con-
erring  either  increased  risk  or  protection  against  AMD.  By
ontrast  to  SNP,  copy  number  variation,  i.e.,  variation  in  the
umber  of  copies  of  a  speciﬁc  DNA  sequence  within  a  gene
ppears  to  be  less  important,  although  a  small  number  of
uch  associations  with  AMD  have  been  recently  reported.27
n  alphabetical  list  of  the  major  genes  currently  associated
ith  AMD,  their  functions,  and  locations  within  the  genome
ogether  with  their  abbreviations  is  given  in  Table  3. cM.  Mousavi,  R.A.  Armstrong
enes involved in immune modulation and the
omplement system
omplement  system  genes
enes  for  the  complement  system  protein  factor  H
CFH),26,28--31 factor  B  (CFB),32 and  factor  3  (C3)22,33 appear
o  exhibit  the  strongest  associations  with  the  risk  of  devel-
ping  AMD.34 A  higher  risk  of  wet  AMD  is  associated  with
olymorphisms  of  the  CFH  gene  and  with  lower  visual  acu-
ty  after26 A  strong  association  between  CFH  and  bilateral
ry  AMD  has  also  been  demonstrated.34 CFH  is  involved  in
he  inhibition  of  the  inﬂammatory  response  mediated  via
3b  by  acting  both  as  a  cofactor  for  cleavage  of  C3b  to  its
nactive  form,  C3bi,  and  by  weakening  the  active  complex
hat  forms  between  C3b  and  factor  B.  C-reactive  protein
nd  polyanionic  surface  markers  such  as  glycosaminoglycans
ormally  enhance  the  ability  of  CFH  to  inhibit  complement.
peciﬁc  mutations  in  CFH  (e.g.,  Tyr402His)  reduce  the  afﬁn-
ty  of  CFH  for  C3f  and  may  also  alter  the  ability  of  CFH  to
ecognize  speciﬁc  glycosaminoglycans.  This  change  results
n  reduced  ability  of  CFH  to  regulate  the  activity  of  com-
lement  proteins  on  critical  surfaces,  such  as  the  retina,
nd  may  lead  to  an  increased  inﬂammatory  response  at  the
acula.  By  contrast,  CFB  is  a  component  of  the  alternative
athway  of  complement  activation.  When  cleaved,  an  active
ubunit  is  formed  which  is  involved  in  the  proliferation  of
re-activated  B-lymphocytes.
erpin  peptidase  inhibitor  (SERPING1)
enetic  variants  of  the  serpin  peptidase  inhibitor  (SERP-
NG1)  gene,  which  regulates  the  activity  of  complement
roteins,  have  recently  been  shown  to  be  associated  with
MD23; the  protein  inhibits  the  ﬁrst  components  of  the  com-
lement  cascade  and  thus  regulates  complement  activation.
enes involved in membrane transport
TP-binding  cassette  rim  protein  (ABCR)
arlier  studies  suggested  that  a  protein  found  in  retinal
od  cells,  viz.,  adenosine  triphosphate  (ATP)-binding  cas-
ette  rim  protein  (ABCR),  may  be  involved  in  a  number
f  ocular  disorders  including  Stargardt’s  macular  dystrophy,
etinitis  pigmentosa  (RP),  cone-rod  dystrophy,  and  AMD.35--38
he  ABCR  protein  comprises  two  structurally  related  halves,
ach  of  which  contains  a  section  which  spans  the  rod  mem-
rane,  and  a  section  which  can  bind  to  ATP,  and  is  abundant
n  the  outer  segments  of  rod  cells  but  absent  from  cone
ells.39 Within  the  rod  outer  segment,  the  protein  is  local-
zed  within  the  rim  region  of  the  rod  membranes  and  aids
he  movement  of  all-trans  retinal  within  the  membrane.40
The  ABCR  gene  is  100  KB  long  and  consists  of  50  exons
anging  in  size  from  33  to  406  nucleotides.41 A  full  length
ranscript  of  the  gene  sequence  was  cloned  in  199842,43ating  that  ABCR  is  an  especially  ‘polymorphic’  gene.44 In
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Table  3  Genes  associated  with  age-related  macular  degeneration  (AMD).
Gene  Function  Location  Association  with  AMD
Apolipoprotein  E  (APOE)  Lipid  transport  19q13.2  Controversial,  possibly  with
early-onset  AMD55--57
ATP-binding  cassette  rim  protein  (ABCR)  Membrane  transport  1p22-p22.1  Controversial,  possibly  with  wet
AMD35--40
Age-related  maculopathy  susceptibility
protein  2  (ARMS2)
Unknown  10q26.13  Wet  AMD,  less  with  dry
AMD48,50,58,59
ATP  synthase  (MT-ATP6) Produces  ATP  from  ADP MtDNA  Implicated  in  AMD60
Complement  factor  H  (CFH)  Inhibition  of  inﬂammatory
response
1q32  Bilateral  dry,  wet  AMD26,28--31,34
Complement  Factor  B  (CFB)  Component  of  alternative
pathway
6p21.3  AMD32
Complement  factor  3  (C3)  Mediates  inﬂammatory
response
19p13.3-p13.2  Wet  AMD22,33
DNA  excision  repair  protein  (ERCC6)  Promotes  complex
formation  at  repair  sites
10q11.23  Possible  association  with  AMD61
Fibroblast  growth  factor  2  (FGF2)  Diverse  biological
functions
4q26  Dry  AMD48
Fibulin  5  (FBLN5)  Polymerization  of  Elastin  14q32.1  AMD49
Hepatic  lipase  (LIPC  Converts  IDL  toLDL  15q21  Reduced  risk  of  wet  and  dry
AMD55
Lysyl  oxidase-like  1  (LOXL1)  Connective  tissue
development
15q24.1  Wet  AMD24,50
Selectin  P  (SELP)  Pl  atel  et/l  eucocyte
Interactions
1q22-q25  Dry  AMD51
Serpin  peptidase  inhibitor  (SERPING1)  Regulates  complement  11q12-q13.1  AMD23
Serum  peptidase  1  (HTRA1)  Regulates  cell  growth  10q25.2-q26.2  Bilateral  wet  AMD21,24,25
Transferrin  (Tf)  Iron  binding  protein  3q29  AMD  in  smokers62,63
Voltage-dependent  calcium  channel  3
(CACNG3)
L-type  calcium  channel
protein
16p12  AMD47
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Aﬁve  early  studies,  however,  there  was  little  agreement  con-
cerning  the  importance  of  the  ABCR  gene  in  AMD.  A  study
of  dry  AMD  in  Japan  concluded  that  there  was  no  relation-
ship  between  allelic  variation  in  ABCR  and  the  disorder38
and  the  study  of  De  la  Paz  et  al.36 concluded  that  ABCR
was  not  a  major  risk  factor.  By  contrast,  a  study  of  wet
AMD37 concluded  that  4%  of  familial  cases  of  AMD  may  be
related  to  ABCR. In  addition,  other  studies  have  concluded
that  possession  of  some  variants  of  the  ABCR  gene  may
increase  susceptibility  to  the  disease.45 Recent  studies  have
also  been  controversial.  Hence,  the  presence  of  three  sig-
niﬁcant  mutations  in  ABCR  was  examined  in  eight  cases  of
wet  AMD,46 the  analysis  failing  to  identify  the  presence  of
disease-causing  mutations  in  the  cases  examined.  However,
ABCR  mutations  causing  the  protein  to  accumulate  in  the
inner  segment  of  rod  cells  have  been  reported  to  be  fre-
quent  in  patients  with  severe  retinal  dystrophies,  including
a  small  number  of  AMD  cases.40
Hence,  ABCR  may  inﬂuence  the  active  transport  of  a  wide
range  of  drugs,  metabolites,  peptides,  and  lipids  and  may
also  be  involved  in  the  transport  of  retinal  derivatives,  phos-
pholipids,  peptides,  or  other  endogenous  substrates  across
the  disk  membrane.  Hence,  disturbed  transport  across  the
membranes  of  retinal  cells  is  one  possible,  albeit  rarer,  route
to  AMD.
v
c
i
toltage-dependent  calcium  channel
amma-3(CACNG3)
oltage-dependent  calcium  channel  gamma-3  (CACNG3)  is  a
rotein  subunit  of  the  L-type  calcium  channel  located  in  the
ell  membrane  and  regulates  trafﬁcking  and  channel  gat-
ng.  Recent  genetic  analysis  has  suggested  there  is  a  gene
ssociated  with  AMD  on  chromosome  16  (16p12).47 At  least
ve  candidate  genes  occur  in  this  region  of  the  chromosome
ut  the  most  likely  to  be  associated  with  AMD  is  CACNG3.
hese  data  suggest  a  possible  link  between  calcium  ion  chan-
el  modulators  in  the  photoreceptors  and  AMD  but  further
esearch  is  necessary  to  establish  the  signiﬁcance  of  this
ene.
enes involved in blood vessel development
nd vascular modulation
 number  of  genes  linked  to  the  development  of  blood
essels  or  modulation  of  vascular  processes  have  been  impli-
ated  in  AMD  and  these  genes  are  interesting  because  of  the
nvolvement  of  the  vasculature  in  wet  AMD  (neovasculariza-
ion).
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ibroblast  growth  factor  2  (FGF2)
ibroblast  growth  factor  2  (FGF2)  is  a  protein  involved  in
arious  biological  processes  including  mitosis,  the  develop-
ent  of  blood  vessels,  wound  healing,  and  tumor  growth.  In
 Spanish  population,  Brion  et  al.48 has  shown  that  although
he  principal  genetic  risk  factors  are  ARMS2  and  CFH, FGF2
ay  also  be  associated  with  some  cases  of  dry  AMD.
ibulin-5
are  forms  of  AMD,  exhibiting  an  autosomal  dominant  pat-
ern  of  inheritance,  may  be  related  to  the  ﬁbulin-5  gene.
ibulin-5  is  an  excreted  extracellular  matrix  protein  and
s  expressed  in  basement  membranes  of  epithelial  cells
nd  developing  blood  vessels  and  is  essential  for  the  poly-
erization  of  elastin.  AMD  patients  were  screened  and  a
tatistically  signiﬁcant  correlation  observed  between  muta-
ions  of  ﬁbulin-5  and  AMD.49
ysyl  oxidase-like  1  (LOXL1)
he  Lysyl  oxidase-like  1  gene  (LOXL1)  codes  for  an  enzyme
nvolved  in  the  development  of  connective  tissue,  including
hat  of  blood  vessels,  and  has  been  shown  to  be  signiﬁcantly
ssociated  with  wet  AMD  in  a  Japanese50 and  a  Korean  pop-
lation  although  the  biological  basis  for  this  association  is
nclear.24
electin-P  (SELP)
he  activity  of  macrophages  and  endothelial  cell  activa-
ion  in  the  pathogenesis  of  AMD  may  also  be  involved  in
MD.51 The  selectin  gene  group  function  as  cell  adhesion
olecules  on  the  surface  of  activated  endothelial  cells  and
latelets  and  is  involved  speciﬁcally  in  the  interactions
etween  platelets  and  leucocytes.  No  single  SNP  of  SELP  is
ighly  correlated  with  AMD,  but  a  polymorphism  of  the  gene
as  been  found  to  be  statistically  associated  with  dry  AMD.51
latelet  and  leukocyte  interactions  promote  thrombus  for-
ation  and  are  active  at  the  sites  of  inﬂammation  but  how
hese  processes  may  contribute  to  dry  AMD,  is  unclear.
enes involved in lipid metabolism
polipoprotein  E  (APOE)
polipoprotein  E  (APOE)  is  a  lipid  transport  protein  essential
or  the  catabolism  of  triglyceride-rich  lipoproteins.  It  trans-
orts  lipoproteins,  fat-soluble  vitamins,  and  cholesterol  to
he  lymph  system  and  then  to  the  blood.  APOE  is  a  poly-
orphic  gene  with  three  major  isoforms,  viz.,  ˇ2,  ˇ3,  and
4.  These  alelic  forms  differ  only  slightly  but  are  sufﬁcient
o  alter  APOE  structure  and  function.  A  pooled  analysis  of
5  studies52 found  associations  between  APOE  alleles  ˇ4  and
2  with  late  AMD  but  there  was  no  interaction  with  gender
r  smoking  behavior.  By  contrast,  Adams  et  al.53 also  found
n  association  between  possession  of  APOE  allele  ˇ2  and
arly  onset  AMD,  an  association  that  was  present  in  non  or
revious  smokers  but  not  in  current  smokers  suggesting  an
D
T
sM.  Mousavi,  R.A.  Armstrong
nteraction  between  genetics  and  smoking.  More  recently,  a
eta-analysis  of  early  onset  AMD  has  suggested  an  associa-
ion  with  APOE.54
epatic  lipase  (LIPC)
he  hepatic  lipase  (LIPC) gene  codes  for  the  enzyme  hepatic
riglyceride  lipase  which  is  expressed  in  liver  and  the  adrenal
lands.  The  principle  function  of  the  enzyme  is  conversion
f  intermediate  density  lipoproteins  (IDL)  to  low  density
ipoproteins  (LDL).  There  may  be  an  association  between  the
roportion  of  different  lipoproteins  and  AMD  in  that  a  spe-
iﬁc  genotype  of  LIPC  has  been  linked  with  a  reduced  risk
f  both  dry  and  wet  forms  of  the  disease.55 Increased  inci-
ence  of  early  AMD  has  been  observed  in  patients  with  raised
-reactive  protein,56 which  is  associated  with  increased  con-
umption  of  lard  and  solid  fat.57 High  triglyceride  levels,
y  contrast,  were  associated  with  a  lower  risk  and  there-
ore,  certain  types  of  lipid  could  be  protective  against  AMD.
n  a  prospective  study,  association  between  AMD  and  fat
ntake  was  examined  by  Cho  et  al.13 Total  fat  intake  of
hose  patients  who  were  the  highest  consumers  was  asso-
iated  with  increased  risk  of  AMD.  In  addition,  linolenic  acid
onsumption  was  associated  with  AMD  whereas  docosahex-
enic  acid  (DHA)  had  a  modest  inverse  relationship  with
MD.  Hence  genes  which  affect  lipid  metabolism  may  alter
he  balance  between  different  types  of  fat  in  the  body  thus
nﬂuencing  risk  of  AMD.
iscellaneous genes
n  addition  to  the  above  groups  of  genes,  a  number  of  genes
f  varied  or  unknown  function  show  some  statistical  associ-
tion  with  AMD.  Their  signiﬁcance  is  more  problematic  and
urther  research  will  be  necessary  to  establish  their  signiﬁ-
ance.
ge-related  maculopathy  susceptibility  protein  2
ARMS2)
ge-related  maculopathy  susceptibility  protein  2  (ARMS2)
s  a  mitochondrial  protein,  currently  of  unknown  function,
hich  may  play  a  role  in  various  diseases  of  the  elderly
ncluding  AMD.58,59 SNP  of  the  ARMS2  gene  are  especially
ssociated  with  wet  AMD  and  the  frequency  of  progression
rom  dry  to  wet  forms  of  the  disease8 but  are  less  associated
ith  dry  AMD.50 In  a  Spanish  population,  ARMS2  has  been
eported  to  be  one  of  the  principal  risk  factors  for  AMD.48
TP  synthase
TP  synthase  is  a mitochondrial  enzyme  important  in  provid-
ng  energy  to  the  cell  via  ATP.  Mutations  of  the  ATP  synthase
ene  have  been  related  to  RP  and  this  gene  may  also  be
mplicated  in  some  cases  of  AMD.60NA  excision  repair  protein  (ERCC6)
he  DNA  excision  repair  protein  gene  (ERCC6) interacts  with
everal  transcription  and  excision  repair  proteins.  Excision
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repair  proteins  remove  mutations  resulting  from  UV  dam-
age  and  result  in  the  removal  of  a  short  single-stranded
segment  of  DNA  containing  the  mutation.  A  new  complimen-
tary  strand  is  then  synthesized  using  the  remaining  strand  as
template.  Disease  can  result  from  genetic  mutations  which
damage  DNA  repair  mechanisms  such  as  ‘Cockayne’s  syn-
drome’,  a  disorder  characterized  by  photosensitivity  and  a
pigment  retinopathy.61 A  study  has  also  suggested  an  asso-
ciation  between  SNP  of  ERCC6  and  AMD61 indicating  that  UV
damage  to  genes  which  is  unrepaired  could  be  a  factor.
Serum  peptidase  1  (HTRA1)
The  serum  peptidase  1  (HTRA1)  gene  encodes  for  a  secreted
serine  protease.21,24,25 The  protein  is  a  secreted  enzyme
proposed  to  regulate  the  availability  of  insulin-like  growth
factor  (IGF)  by  cleaving  IGF-binding  protein.  IGF  binds
to  insulin-like  growth  receptor  thus  initiating  intracellu-
lar  signaling  and  subsequently,  stimulating  cell  growth  and
inhibiting  apoptosis  (programmed  cell  death).  Hence,  HTRA1
may  inhibit  cell  death  in  the  retina  and  mutations  in  this
gene  result  in  increased  cell  losses.  Tong  et  al.25 empha-
sized  the  importance  of  gene  interactions;  HTRA1  plays  a
signiﬁcant  role  in  AMD  when  it  is  found  in  combination  with
ARMS2.
Transferrin  (Tr)
Transferrin  (Tr)  is  an  iron-binding  blood  plasma  glycopro-
tein  which  controls  the  level  of  free  iron  in  biological
ﬂuids.62 Oxidative  stress  is  regarded  as  a  major  risk  fac-
tor  for  AMD  and  increased  levels  of  reactive  oxygen  species
(ROS)  are  produced  by  reactions  catalyzed  by  iron  in  the
retina.  Hence,  changes  in  iron  metabolism  genes  may  be
involved  in  AMD.  Recently,  SNP  in  the  Tr  gene  have  been
shown  to  be  signiﬁcantly  associated  with  AMD  especially
in  smokers63 emphasizing  the  interactions  that  may  occur
between  genetic  susceptibility  and  environmental  risk  fac-
tors.
Genes and the pathogenesis of AMD
The  most  important  genes  implicated  in  AMD  appear  to  be
those  involved  in  immune  modulation  and  the  complement
system  such  as  CFH,26,28--31 CFB,32 C3,22,33 and  SERPING123
strongly  suggesting  that  inﬂammatory  processed  are  impor-
tant  in  AMD.  It  has  been  concluded  that  SNP  in  CFH, C3,
HTRA1,  and  SERPING1  together  could  account  for  45%  of
the  risk  of  developing  AMD.23 Genes  associated  with  mem-
brane  transport,  e.g.,  ABCR35--38 and  CACNG 47,  the  vascular
system,  e.g.,  FGF2,22 LOXL121,30 and  SELP,31 and  with  lipid
metabolism,  e.g.,  APOE52--54 and  LIPC55 are  also  involved.  Of
these,  the  vascular  genes  are  of  particular  interest  because
of  the  involvement  in  neovascularization.  In  addition,  a
series  of  other  putative  genes  of  variable  or  unknown  func-
tion  could  be  involved  in  AMD  including  ARMS2,58,59 ATP
synthase,60 ERCC6,61 and  HTRA121,24,35 and  it  is  likely  that
many  further  genes  will  be  identiﬁed.
Hence,  there  are  likely  to  be  multiple  pathways  leading
to  the  same  ultimate  pathology  in  AMD,  i.e.,  loss  of  retinal
photoreceptors.  Nevertheless,  it  is  possible  that  carriers  of
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igh-risk  genotypes  may  show  detectable  and  speciﬁc  visual
hanges  before  overt  pathology  is  present.  Feigle  et  al.64
ssessed  the  critical  fusion  frequency  (CFF)  in  individuals
ith  normal  vision  who  were  carriers  of  high-risk  variants  of
enes  such  as  CFH, LOC, and  HTRA1. CFF  mediated  by  rods
nd  cones  was  signiﬁcantly  reduced  in  gene  variant-positive
ather  than  gene  variant-negative  individuals  although  CFF
ediated  by  cones  alone  was  unaffected.  This  was  the  ﬁrst
tudy  to  relate  early  AMD  risk  genotypes  to  visual  function
uggesting  that  there  may  be  many  other  gene/vision  rela-
ionships  to  be  identiﬁed  in  AMD.
rotective factors
arious  nutritional  factors  may  be  involved  in  the  patho-
enesis  of  AMD  including  anti-oxidants  and  anti-oxidant
o-factors,  a  number  of  vitamins,  zinc,  and  anti-free  radicals
uch  as  lutein,  zeaxanthin  and  components  of  the  mem-
rane  of  photoreceptor  cells.65 Consumption  of  omega-3
atty  acids  in  combination  with  anti-oxidants  has  been  sug-
ested  as  a preventative  strategy66 but  no  fully  developed
ouble  blind  studies  have  been  carried  out  to  date  to  test
his  hypothesis.  Eating  more  cold-water  ﬁsh  rather  than  red
eat  and  adding  nuts  to  the  diet  have  all  been  suggested  to
educe  the  risk.64 For  example,  Chua  et  al.14 suggested  that
 40%  reduction  in  early  AMD  could  be  achieved  by  chang-
ng  to  a  diet  with  signiﬁcantly  increased  ﬁsh  consumption.67
n  addition,  there  is  evidence  that  supplementing  the  intake
f  DHA  and  eicosapentaemic  acid  (EPA)  and  reducing  dietary
lycemic  index  (dGI)  may  be  protective  against  AMD  in  the
Age  Related  Eye  Disease  Study  (AREDS)  trial.17
A  review  of  all  randomized  controlled  trials  comparing
nti-oxidant  vitamins  concluded,  however,  that  there  was
ittle  beneﬁt  of  any  anti-oxidant  combination  in  AMD.68 They
lso  concluded  that  there  was  accumulating  evidence  that
either  vitamin  E  nor  -carotene  in  themselves  could  pre-
ent  or  delay  the  onset  of  AMD.  In  addition,  Delcourt  et  al.69
tudied  the  relationship  between  nutrition  and  AMD  and
ound  that  individuals  taking  the  antioxidants,  lutein,  zea-
anthin,  and  omega-3  poly  unsaturated  fatty  acids  had  a
ower  risk  of  AMD.  A  similar  result  was  reported  by  Lecerf
nd  Desmettre.70 By  contrast,  Chong  et  al.71 using  meta-
nalysis,  studied  the  effect  of  dietary  anti-oxidants  in  nine
rospective  cohorts  and  three  random  clinical  trials.  Pooled
esults  suggested  that  vitamins  A,  C,  and  E,  zinc,  lutein,  zea-
anthin,  carotene,  P-cryptoxanthin,  and  lycopene  had  little
r  no  effect  on  preventing  early  AMD.  However,  there  was
vidence  that  antioxidant  supplements  containing  zinc  could
revent  visual  loss  in  individuals  with  early  AMD.72
odiﬁable risk factors
everal  studies  have  proposed  additional  lifestyle  changes
o  reduce  the  lifetime  risk  of  AMD  that  should  be  consid-
red  in  patients  in  high  genetic  risk  categories.  Hence,  high
at  intake  may  be  associated  with  an  increased  risk  of  AMD
n  both  women  and  men.  Reducing  fat  intake  to  this  level
eans  reducing  the  consumption  of  red  meat  and  dairy  prod-
cts  such  as  whole  milk,  cheese,  and  butter  which  are  high
n  saturated  fats.  Higher  red  meat  intake  has  been  posi-
ively  associated  with  early  AMD  whereas  consumption  of
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hicken  may  be  negatively  associated  with  AMD.73 There
s  considerable  evidence  that  the  incidence  of  AMD  varies
ith  both  ethnicity  and  geographical  location  which  could
e  attributed  in  part  to  varying  diet.  Hence,  the  risk  of  AMD
aries  among  Americans  of  different  Asian  origin74, overall,
.4%  of  Asian  Americans  having  dry  and  0.49%  wet  AMD,  Chi-
ese  and  Pakistani  Americans  having  a  signiﬁcantly  increased
isk  of  dry  AMD  compared  with  non-hispanic  whites.  By  con-
rast,  Japanese  Americans  have  a  29%  decreased  risk  of
ry  AMD.74 There  were  no  signiﬁcant  differences  in  the  risk
f  wet  AMD  in  Asian  Americans  of  any  ethnicity  compared
ith  white  Americans.  Outside  the  US,  a  Japanese  study
t  Funagata75 found  that  the  prevalence  of  early  AMD  in
ndividuals  greater  than  35  years  of  age  was  3.5%,  and  of
ate  AMD  0.5%,  while  the  age-standardised  prevalence  in
he  right  eye  was  4.1%.  In  rural  China,  prevalence  of  wet
nd  dry  AMD  is  1.45%  and  1.55%  respectively,  increasing  with
ge.76 An  overview  of  epidemiological  studies  from  around
he  world72 suggests  prevalence  of  early  AMD  is  similar  in  the
hite,  black,  and  hispanic  populations,  but  that  whites  have
 greater  prevalence  of  late  AMD.  Hence,  prevalence  stud-
es  provide  considerable  evidence  that  environmental,  and
ifestyle  differences  among  populations  as  well  as  genetic
ariation  are  likely  to  be  involved  in  determining  the  risk  of
MD.
isk factor assessment scores
he  identiﬁcation  of  speciﬁc  genetic  defects  leads  to  the
ossibility  of  more  widespread  screening  for  AMD  especially
n  affected  families  and  hence,  the  possibility  of  identifying
symptomatic  carriers  of  the  disease.  A  review  of  research
o  date  suggests  that  smoking  is  the  single  most  important
odiﬁable  risk  factor  for  AMD.9--12 Studies  taken  collectively
uggest  that  long-term  smoking  is  associated  with  approxi-
ately  a  doubling  of  the  risk  of  late-onset  AMD.  Hence,  it
s  particularly  important  that  patients  with  a  familial  his-
ory  of  the  disease  should  cease  smoking.  A  risk  assessment
odel  has  been  developed  for  advanced  AMD  and  is  avail-
ble  for  online  use.7 Based  on  data  from  2846  AMD  patients
ollowed  over  9.3  years,  Cox  proportional  hazard  analysis
as  used  to  assess  the  signiﬁcance  of  demographic,  envi-
onmental,  phenotypic,  and  genetic  covariates.  The  ﬁnal
odel  incorporates  age,  smoking  behavior,  family  history,
nd  genetic  variation  (especially  of  CFH  and  ARMS2) to  pre-
ict  the  risk  of  AMD.7 Grassman  et  al.77 have  constructed  a
enetic  risk  score  for  AMD  based  on  13  ‘at  risk’  variations  of
ight  individual  genes.  AMD  patients  younger  than  75  years
f  age  had  a  signiﬁcantly  higher  score  compared  with  those
atients  older  than  75.  In  addition,  Seddon  et  al.6 have  pro-
osed  a  prediction  model  for  the  risk  of  advanced  AMD  based
n  genetic,  demographic  and  environmental  variables.  This
odel  included  several  genetic  variants  including  CFH, LOC,
2,  CFB, and  C3,  all  of  which  were  related  to  the  prevalence
f  advanced  AMD,  and  all,  with  the  exception  of  CFB, sig-
iﬁcantly  related  to  the  progression  to  advanced  AMD.  In
ddition,  smoking  was  independently  related  to  AMD  with  a
ultiplicative  joint  effect  with  genotype.  These  advances
ave  also  resulted  in  the  development  of  speciﬁc  screening
ests  for  AMD,  such  as  the  ‘macula  risk  test’  which  involves
aking  a  sample  of  cells  from  the  cheek  of  the  patient  forM.  Mousavi,  R.A.  Armstrong
enetic  analysis.78 The  results  of  the  test  include  a  risk  esti-
ate  based  on  the  genetic  polymorphisms  identiﬁed  and
enetic  counselling  support.  The  test  has  ﬁve  categories
f  risk  determined  by  an  algorithm  that  takes  into  account
enetics  and  also  smoking  history.  Hence,  risk  category  1
s  associated  with  a  lifetime  risk  of  0.65--4.6%  whereas  risk
ategory  4  is  associated  with  a  55--94%  lifetime  risk.
onclusion
odiﬁable  risk  factors  for  AMD  should  be  discussed  with
atients  whose  lifestyle  and/or  family  history  place  them  in
n  elevated  risk  category.  Protective  modiﬁcations  include:
essation  of  smoking,  sunglass  protection  under  conditions
f  elevated  light  intensity,  dietary  modiﬁcations  to  reduce
ntake  of  saturated  fats  and  increase  omega  3  fatty  acids.
alculation  of  AMD  risk  using  current  models  should  be  rec-
mmended  as  a  tool  for  patient  education.  Furthermore,
MD  management  frequency  may  be  inﬂuenced  by  an  assess-
ent  of  genetic  risk,  as  such  provisions  are  likely  to  become
ore  widely  available.  Interactions  between  different  genes
nd  between  genes  and  the  environment  also  play  a  promi-
ent  role  in  the  development  of  AMD  and  are  likely  to  be
roﬁtable  areas  of  future  research.
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